New medication successfully protected nonhuman primates against a fatal infection of all strains of the deadly Ebola virus in a single dose, reports a new study. The findings of the study are published in the journal Cell Host & Microbe.
Dr. Thomas Geisbert, a world-renowned Ebola researcher at The University of Texas Medical Branch, said that previous therapeutics typically were of the "one bug, one drug" variety. But because of the unpredictable nature and variety of the Ebola virus, scientists have been seeking a way to protect against different strains of the virus.
Ebola Virus is Targeted at Different Sites by the Human Immune System
Human immune system's mode of action against the Ebola virus has been discovered. This provides a breakthrough to develop antibody-based therapies that could help treat patients affected by this fatal illness.
Advertisement
‘The ability to swiftly and efficiently provide protection against all Ebola viruses in one single dose would decrease the burden on health care workers in the field during outbreaks, particularly in regions that have a less-developed infrastructure.’
Read More..
Tweet it Now
Read More..
"Our experimental drug can protect against all forms of Ebola known to harm people, suggesting that it will continue to protect people if the Ebola viruses evolve over time," said Geisbert, who is a professor of microbiology and immunology at UTMB.
The team of scientists demonstrated that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections of caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain that caused the 2013-16 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo.
![New Ebola Virus Antibody Paves the Way for Future Vaccines and Therapy]( "New Ebola Virus Antibody Paves the Way for Future Vaccines and Therapy")
Natural human antibodies isolated from the blood of an Ebola survivor has been shown to neutralize all three major disease-causing Ebola viruses.
"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, president of Mapp Biopharmaceutical Inc. "Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions. The ability to quickly and efficiently protect against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure."
Source: Eurekalert
New Ebola Virus Antibody Paves the Way for Future Vaccines and Therapy
Natural human antibodies isolated from the blood of an Ebola survivor has been shown to neutralize all three major disease-causing Ebola viruses.
Advertisement
"We were able to protect the nonhuman primates against all the Ebola species plaguing people at a single low dose," said Larry Zeitlin, president of Mapp Biopharmaceutical Inc. "Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions. The ability to quickly and efficiently protect against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure."
Source: Eurekalert
Interferon Drug Promises Hope for Ebola Virus Treatment
Ebola virus causes fatal illness, interferon drug may show promise for treatment, reveals study.
Advertisement
 New Protein Against Ebola Virus in Human Cells IdentifiedDrugs that simulate functions of Ebola virus protein could become target for discovering new drugs against Ebola virus | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
The scientists discovered that when the stem cells in the hair follicle are made softer, they have a higher chance of growing hair.
A combinatorial therapy provided promising beneficial results among people with ischemic stroke.
In Parkinson's disease patients voice disorders are quite common. A new combination therapy had greater effects on the voice.
New study findings delineate how aging affects the immune response following Spinal cord injury (SCI) and highlight the participation of the spinal cord meninges in repair.
A recent clinical trial suggests that the first medication therapy to reduce the progression of nearsightedness in children could be on the way.